Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Champignon Brands Inc. on Behalf of Investors

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Champignon Brands Inc. ("Champignon" or the "Company") (OTC: SHRMF ) investors concerning the Company's possible violations of the federal securities laws.

If you suffered a loss on your Champignon investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/champignon-brands-inc/ . You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On June 22, 2020, Champignon announced that the Company had "been selected for continuous disclosure review by the British Columbia Securities Commission (the "Commission") and "in connection with the review, the Commission had issued a cease trade order suspending in the securities of the Company pending the filing of business acquisition reports."

On this news, the Company's stock price fell 24% to close at $0.500 per share on June 22, 2020, thereby damaging investors.

On September 15, 2020, the Company issued a press release stating, amongst other things, "the Commission issued a replacement cease trade order . . . , pending the filing of a revised material change report . . . in connection with the acquisition by the Company of AltMed." Champignon further stated that "the acquisition of AltMed should be treated as a reverse-takeover."

On this news, Champignon's stock price fell 5% to close at $0.271 per share on September 16, 2020, thereby damaging investors.

On February 17, 2021, Champignon announced that it would restate its financial statements for the three and six month periods ended March 31, 2020. Specifically, "the Company previously recognized intangible assets in connection with" certain acquisitions, and "management determined that . . . the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company's statement of loss and comprehensive loss." Champignon also stated that "a shareholder and contracted consultant (the ‘Consultant') of the Company was a related party with respect to" those acquisitions.

On this news, Champignon's stock price fell 10% to close at $0.687 per share on February 17, 2021, thereby damaging investors further.

Follow us for updates on LinkedIn , Twitter , or Facebook .

Whistleblower Notice: Persons with non-public information regarding Champignon should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com .

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM's attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal , The Financial Times , Bloomberg Businessweek , Reuters , the Associated Press , Barron's , Investor's Business Daily , Forbes , and Money .

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com
shareholders@glancylaw.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TRD) receive their care in the United States.

HealthPort offers an integrated model of care aimed at helping those with behavioral health conditions and people impacted by poverty, disability and trauma. HealthPort is an evidence-based practice supporting thirteen dimensions of social determinants of health, including the coordination of an integrated outpatient mental health and addictions health clinic. HealthPort has been operating facility, residential, and mobile based interventions of care in the lower Eastern Shore of Maryland for the past 45 years.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass management will host a conference call at 8:00 am ET (1:00 pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Participants received a single dose of either 25 mg of COMP360 or placebo
  • On track for disclosure of top-line 6-week primary endpoint results in late June

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • Screening closed for all sites and final participants being scheduled for dosing
  • On track for top-line 6-week primary endpoint results in late Q2

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Highlights:

  • 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy for a single dose of 25mg lasting about 12 weeks and substantially longer in a subgroup
  • Findings published in the March edition of the Journal of Clinical Psychiatry

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways to Participate in Stifel Virtual CNS Forum

COMPASS Pathways Plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18 th , 2025.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×